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Abstract 
This review highlights ten important advances in the neuromuscular disease field that either were first report-
ed in 2019, or have reached a broad consensus during that year. The overarching topics include (i) new / 
emerging diseases; (ii) advances in understanding of disease etiology and pathogenesis; (iii) diagnostic advanc-
es; and (iv) therapeutic advances. Within this broad framework, the individual disease entities that are dis-
cussed in more detail include myoglobinopathy, POPDC3-mutated limb-girdle muscular dystrophy, neuromus-
cular adverse events associated with the immune checkpoint inhibition therapy, neuroglial stem cell-derived 
inflammatory pseudotumor of the spinal cord and spinal cord roots, acute flaccid myelitis, congenital myopa-
thies, idiopathic inflammatory myopathies (with particular emphasis on immune-mediated necrotizing myopa-
thies and sporadic inclusion body myositis), spinal muscular atrophy, and Duchenne muscular dystrophy. In 
addition, the review highlights several diagnostic advances (such as diagnostic RNA sequencing and develop-
ment of digital diagnostic tools) that will likely have a significant impact on the overall neuromuscular disease 
field going forward. 
Keywords: Anterior horn disease, Congenital myopathy, Inflammatory myopathy, Muscular dystrophy, Neuropathy, Radiculopathy, 
RNA-seq, Gene therapy 
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AAV, adeno-associated virus; AFM, acute flaccid 
myelitis; AI, artificial intelligence; ASM, antisynthetase 
syndrome-associated myositis; ASO, antisense oligonu-
cleotide; CASA, chaperone-assisted selective autophagy; 
DM, dermatomyositis; DMD, Duchenne muscular dys-
trophy; EMA, European Medicines Agency; EV, enterovi-
rus; FDA, Federal Drug Administration; HMGCR, 3-
hydroxy-3-methylglutaryl-CoA reductase; IFN, interfer-
on; IIM, idiopathic inflammatory myopathy; IMNM, 
immune-mediated necrotizing myopathy; irAE, immune-
related adverse event secondary to immune checkpoint 
inhibition; irMG, myasthenia gravis secondary to im-
mune checkpoint inhibition; irMyositis, inflammatory 
myopathy secondary to immune checkpoint inhibition; 
irNeuropathy, immune-mediated neuropathy secondary 
to immune checkpoint inhibition; MHC, major histocom-
patibility complex; mNGS, metagenomic next generation 
sequencing; MSA, myositis-specific antibodies; MxA, 
myxovirus resistance protein A; NM, nemaline myopa-
thy; NMD, neuromuscular disease; n-SCIPT, neuroglial 
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stem cell-derived inflammatory pseudotumor; PM, pol-
ymyositis; RNA-seq, transcriptome analysis (RNA se-
quencing); sIBM, sporadic inclusion body myositis; SMA, 
spinal muscular atrophy; SRP, signal recognition particle; 
TEMRA cells, terminally differentiated effector memory 
T cells; WES, whole exome sequencing 
Introduction 
2019 was an exciting year for the neuromuscular 
disease (NMD) field, with important developments on 
multiple fronts and in many different disease categories. 
In this review paper, I will summarize ten 2019 NMD 
discoveries that I consider to be most important and/or 
interesting; they are grouped in four different “discovery 
clusters” and listed in no particular order. (Like most 
classifications, this one is not perfect – a few discoveries 
included in the “etiology/pathogenesis cluster” have 
direct implications for diagnostics and/or treatment of 
NMDs – but I hope it will improve the overall readability 
of the review.) 
Newly defined / emerging neuromus-
cular diseases 
1. Newly defined genetic diseases 
Even as our understanding of the NMD genetics 
inches closer to completion, new genetic NMDs continue 
to be defined; in this review, I will summarize key fea-
tures of two particularly interesting entities that were 
first characterized in 2019. 
Myoglobinopathy is caused by the c.292C>T, 
p.His98Tyr mutation in myoglobin, a small cytoplasmic 
hemoprotein that buffers intracellular O2 concentration 
and regulates the intracellular redox potential in cardi-
omyocytes and type 1 muscle fibers (Olive et al., 2019). 
Through an effort that involved two research teams on 
two different continents, this mutation was detected in 
14 individuals from six different families, all of whom 
were initially identified based on the unique clinicopath-
ologic features of their disease. Clinically, myoglobinopa-
thy presents with a weakness of the proximal lower limb 
and axial muscles; the symptoms start in the fourth to 
fifth decade and are slowly progressive, ultimately in-
volving distal lower limb, upper limb, and respiratory 
muscles. Creatine kinase levels are usually normal, while 
cardiac involvement is clinically apparent in approxi-
mately half of the affected individuals. Pathologically, all 
muscle biopsies (as well as the hearts from two individu-
als who underwent autopsy) showed characteristic sar-
coplasmic bodies that are brown on H&E stain, red on 
modified Gomori trichrome stain, and highly electron 
dense on electron microscopy (Fig. 1); interestingly, 
these sarcoplasmic inclusions rarely contain myoglobin 
and seem to be a product of increased lipid oxidation. 
(Late stage biopsies also show chronic myopathic chang-
es and autophagic impairment including rimmed vacu-
oles.) Although additional work will be required to fully 
elucidate the molecular mechanisms underlying this 
newly defined disease, the initial biochemical experi-
ments suggest that mutant myoglobin is more prone to 
the loss of the heme moiety and is associated with ele-
vated intracellular superoxide levels, suggesting that 
impaired redox balance plays a role in the pathogenesis 
of this disease. 
A different, purely genetic approach was used to 
define a new autosomal recessive form of limb-girdle 
muscular dystrophy that is caused by biallelic mutations 
in POPDC3 gene: 5 affected individuals from 3 different 
families were identified via exome sequencing of a co-
hort of 1500 patients with presumed genetic limb-girdle 
weakness and elevated creatine kinase levels; their mus-
cle biopsies showed dystrophic features of variable se-
verity (Vissing et al., 2019). POPDC3 (Popeye domain 
containing 3) gene encodes a membrane protein that 
regulates cAMP signaling, is highly expressed in skeletal 
and cardiac muscles, and has not yet been associated 
with any human disease. Interestingly, patients with 
POPDC3 mutations do not show a cardiac phenotype, 
while mutations in two other members of the same gene 
family (POPDC1 and POPDC2) cause a cardiac phenotype 
(generally a conduction disorder) accompanied by a 
variable skeletal muscle involvement (De Ridder et al., 
2019; Vissing et al., 2019). The pathogenesis of this new 
disorder remains to be elucidated; however, initial stud-
ies suggest a loss-of-function mechanism that leads to 
altered cAMP modulation. 
2. Emerging therapy-related diseases 
Introduction of new therapies has led to the emer-
gence of unusual or completely novel NMD phenotypes; 
in 2019, two new NMD categories, previously described 
only in individual case reports or small case series, have 
been more thoroughly defined. 
Immune-checkpoint inhibitor therapy has revolu-
tionized treatment of patients with advanced cancers, 
but is often associated with immune-related adverse 
events (irAEs) that most commonly affect the skin, GI 
tract, and endocrine glands, as well as the PNS. Neuro-
muscular irAEs can be severe and include myasthenia 
gravis (irMG), myopathy (irMyositis), and peripheral 
neuropathy (irNeuropathy; most commonly acute de-
myelinating polyradiculoneuropathy) (Johansen et al.,
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Figure 1. Ultrastructural characterization of sarcoplasmic bodies, the morphological hallmark of myoglobinopathy. Electron micro-
graphs (a–d) show collections of highly electron-dense bodies with some less dense material at their periphery. The sarcoplasmic bodies 
are seen under the sarcolemma (a), often next to the nuclei. Some sarcoplasmic bodies are surrounded by a membrane (b). Sarcoplas-
mic bodies of different electron densities are seen near several vesicular structures (c) and were observed in the cardiac muscle ob-
tained post mortem from one of the affected individuals (d). Electron micrographs (e–g) and the corresponding Nanoscale Secondary 
Ion Mass Spectrometry images (h–j). Blue indicates sulfur (32S), red phosphorus (31P), and green iron (56Fe), respectively. Sarcoplasmic 
bodies are seen interspersed between the myofibrils (e), next to nuclei (f), or inside an autophagic vacuole (g). Note the high-sulfur 
signal in the sarcoplasmic bodies (h–j), and the iron signal (green dots within the sarcoplasmic bodies in i, j). Scale bar in a = 2 µm, b 
 = 5 µm, c = 0.5 µm, d = 1 µm, h–j = 4 µm.  [This figure and its legend were adopted from Figure 5 in (Olive et al., 2019); this use is permit-
ted under the Creative Commons Attribution 4.0 International License.] 
 
2019; Mohn et al., 2019; Psimaras et al., 2019). While 
these neuromuscular irAEs share some commonalties 
with their sporadic counterparts, several unique features 
have emerged. For example, up to 25% of the patients 
show more than one neuromuscular irAE, with the com-
bination of irMG and irMyositis encountered most often 
(Johansen et al., 2019). Furthermore, irMG is more likely 
to be negative for AChR antibodies than idiopathic MG, 
while irMyositis is more likely to involve oculomotor and 
bulbar muscles than any of idiopathic inflammatory 
myopathies (IIMs); these features make clinical distinc-
tion between irMG and irMyositis difficult in many cases 
(Johansen et al., 2019; Mohn et al., 2019). In addition, 
irMyositis often involves axial muscles, while IIMs do not 
(Touat et al., 2018). Finally, a significant fraction of pa-
tients with irMyositis shows cardiac involvement, which 
is not typically seen in IIM patients and has a poor prog-
nosis (Anquetil et al., 2018; Johansen et al., 2019; Mohn 
et al., 2019). Interestingly, while the rates of irNeuropa-
thies (as well as the overall irAE rates) are higher in pa-
tients treated with ipilimubab (the anti-CTLA-4 anti-
body), irMG and irMyositis are particularly common in 
patients treated with nivolumab or pembrolizumab (the 
PD-1 blocking antibodies) (Mohn et al., 2019). The path-
ogenesis of neuromuscular irAEs is incompletely under-
stood, but is thought to involve both type IV (T cell-
mediated) and type II (antibody-mediated) immune 
mechanisms (Psimaras et al., 2019). On a tissue level, 
irMyositis can take multiple forms but the most com-
monly observed pattern [perimysial foci of CD8+ T cells
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Figure 2. Myositis secondary to therapy with immune checkpoint inhibitors (irMyositis). A representative H&E-stained cryosection (a) 
shows patches of dense perimysial inflammation that focally extend into the endomysium and abut clusters of degenerat-
ing/regenerating muscle fibers; away from the inflammatory foci, muscle fibers have a relatively normal appearance. Immunohisto-
chemistry for CD8 (b) and histochemistry for acid phosphatase (c) show that the inflammatory infiltrate largely consists of cytotoxic T 
cells and macrophages, respectively. The patient was treated with pembrolizumab and presented with evidence of myocarditis as well 
as limb and bulbar weakness approximately 6 weeks following the last antibody dose. Scale bars: a, 100 µm; b-c, 50 µm. 
 
and CD68+ macrophages that are associated with necro-
sis of adjacent muscle fibers; Touat et al. (2018) and Fig. 
2] is distinct from the patterns seen in IIMs.  Interesting-
ly, in some cases identical clonal CD8+ cells have been 
detected within the cancer tissue, skeletal muscle, and 
myocardium, suggesting that cross-reactivity between 
cancer cells and myocytes plays at least some role in the 
pathogenesis of irMyositis (Psimaras et al., 2019). 
In recent years, stem cell treatments have also ris-
en in popularity, although they have no documented 
health benefits and are – at least for now – completely 
unregulated. In 2019, it was recognized that one rela-
tively common form of stem cell treatment, intrathecal 
injection of allogeneic stem cells, can lead to develop-
ment of distinctive lesions of the lumbosacral spinal cord 
and spinal cord nerve roots. These lesions, named neu-
roglial stem cell-derived inflammatory pseudotumors [n-
SCIPTs; (Sloan et al., 2019)], can clinically mimic inflam-
matory and neoplastic disease processes and usually 
consist of a haphazardly organized neuroglial tissue that 
resembles a low-grade neuroglial tumor (Fig. 3); typical-
ly, there is at least focal inflammatory infiltrate, which 
likely represents a host immune response to foreign 
antigens. While it seems likely that direct injection of 
allogeneic stem cells into other parts of the body could 
lead to development of stem-cell derived pseudotumors 
with non-neuroglial differentiation, only neuroglial 
SCIPTs have been reported to date (Sloan et al., 2019). 
From a diagnostic perspective, it is critical to be aware of 
the n-SCIPT existence, so that these lesions (which at the 
moment seem to be best handled through watchful 
waiting) are distinguished from the spinal cord tumors 
that would generally warrant a more aggressive treat-
ment. 
Advances in understanding of etiology 
and pathogenesis of neuromuscular 
diseases 
3. Acute flaccid myelitis: Mounting evidence for 
causation by non-polio enteroviruses 
Acute flaccid myelitis (AFM) is a clinical syndrome 
characterized by flaccid limb weakness that develops 
acutely and has a lower motor neuron pattern; the cur-
rent diagnostic criteria also include spinal cord imaging 
findings suggestive of anterior myelitis (Messacar et al., 
2018). 
The most common form of AFM used to be polio-
myelitis, which is caused by poliovirus [a member of the 
En terovirus (EV) genus]; as a result, AFM became rare 
worldwide after introduction of the anti-polio vaccine in 
the 1950s. A small number of AFM cases in the period 
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Figure 3. Neuroglial stem cell-derived inflammatory pseudo-
tumor (n-SCIPT). A representative H&E-stained paraffin section 
(a) shows a spinal cord nerve root surrounded by haphazardly 
organized but otherwise mature-appearing neuroglial tissue. 
Neurofilament immunohistochemistry (b) highlights intensely 
stained but disorganized nerve cell processes (arrowheads) 
that surround the centrally located nerve root (arrow); the 
tissue at the periphery of the specimen shows glial differentia-
tion and is neurofilament-negative. Chronic inflammatory 
infiltrate was apparent on other sections; for additional images 
and clinical history details, see the original publication (Sloan et 
al., 2019). Scale bar, 100 µm. 
 
from 1970-90 was attributed to infection with EV-A71 
and a few other viruses (Dyda et al., 2018; Messacar et 
al., 2018).  Since 2012, however, AFM has started to 
increase in incidence. The current form of this disease, 
first documented in California, is characterized by limb 
paralysis that occurs 5-7 days after a flu-like respiratory 
illness; it primarily affects young children (3-9 years of 
age) and peaks in incidence every other year during the 
summer/fall season. The largest number of confirmed 
cases (>500 to date) has been reported in the US, with 
sporadic cases confirmed throughout the world (Schu-
bert et al., 2019). 
In 2014, the peak of AFM incidence has shown a 
temporal and geographic overlap with the outbreak of 
EV-D68 infection, raising the possibility that EV-D68 
(which rarely caused human disease prior to 2008) might 
be the cause of recent AFM outbreaks (Dyda et al., 
2018). Indeed, EV-D68 infection meets many of the 
Bradford-Hill criteria (nine principles applied to examine 
causality) that are required to establish it as a cause of 
AFM (Dyda et al., 2018; Messacar et al., 2018). In partic-
ular, AFM-like disease can be recapitulated in a mouse 
model through infection with a 2014 strain (but not the 
originally isolated 1962 strain) of EV-D68, suggesting 
that neurotropism might have emerged only recently in 
EV-D68 evolution (Hixon et al., 2017). However, 2016 
AFM cases have not shown a clear association with an 
EV-D68 outbreak, raising doubts about the causal asso-
ciation between EV-D68 and AFM (Dyda et al., 2018). 
Moreover, EV has not been detected in the respiratory 
or GI specimens from more than half of AFM children, 
and EV RNA is very rarely detected in the CSF of AFM 
patients (Schubert et al., 2019); thus, concerns have 
persisted that recent AFM outbreaks might be caused by 
a still unidentified pathogen or an autoimmune mecha-
nism. 
The 2019 study by Schubert et al. has used a multi-
pronged approach [metagenomic ultra-deep next gener-
ation sequencing (mNGS) of the CSF to detect the path-
ogen-derived nucleic acids, and antiviral antibody detec-
tion in the CSF using VirScan phage display library and EV 
ELISA) to analyze 42 AFM cases (covering all outbreaks 
from 2012-2018) and 58 neurologic disease controls. 
Except for one already known EV-D68-positive case, 
mNGS failed to discover any CSF pathogens in either 
group. However, VirScan and EV ELISA revealed signifi-
cantly higher levels of anti-EV antibodies in cases com-
pared to controls, providing a strong support for EVs as 
causative agents of all recent AFM outbreaks. Interest-
ingly, CSF from AFM cases commonly contained antibod-
ies targeting more than one EV; thus, viral detection in 
the spinal cord tissue will likely be required to definitive-
ly establish which EV species can cause AFM. In addition, 
further work will be required to determine the sensitivi-
ty and specificity of CSF EV serology in AFM diagnosis 
(Schubert et al., 2019). 
4. Congenital myopathies: New pathogenetic 
mechanisms 
Congenital myopathies are a group of genetically 
and clinically heterogeneous disorders that typically 
present early in life with weakness / hypotonia and de-
layed motor development, and are subsequently charac-
terized by a stable or slowly progressive disease course. 
Histopathologic findings are variable and include type 1 
fiber predominance and atrophy, cores and/or mini-
cores, mislocalization of intracellular organelles (includ-
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ing nuclei), and various sarcoplasmic inclusions (such as 
nemaline rods, caps, and cytoplasmic bodies).  The well-
established pathogenetic mechanisms include impair-
ments of calcium homeostasis, excitation-contraction 
coupling, sarcomeric filament assembly, force genera-
tion, and membrane remodeling. Excitingly, this mecha-
nistic spectrum has been significantly widened by the 
work published in 2019. Some of the newly discovered 
mechanisms include (i) cell cycle acceleration accompa-
nied by reduced cell growth (Villar-Quiles et al., 2019), 
(ii) impaired redox balance (Lornage et al., 2019), (iii) 
altered muscle kinetics due to impaired sarcomere re-
laxation (de Winter et al., 2020), and (iv) nuclear dys-
function secondary to impaired contractility (Ross et al., 
2019); these last two studies are particularly ground-
breaking and will therefore be described in a greater 
detail. 
Nemaline myopathy (NM) can be caused by muta-
tions in at least 13 genes, the great majority of which 
encode proteins that either form thin filaments or are 
associated with these filaments. A recent tour-de-force 
study by de Winter et al. (2020; advanced electronic 
publication in 2019) has established that KBTBD13 (kelch 
repeat and BTB domain containing 13), the mutations in 
which cause NEM6 subtype of NM, is also an actin-
binding protein; when mutated, KBTBD13 impairs sar-
comere relaxation by altering the structure of thin fila-
ments. Specifically, thin filaments are more tightly 
wound and stiffer than normal when they are bound to 
mutant KBTBD13R408C; this change in the thin filament 
compliance disrupts the positive feedback loop that is 
required for thin-thick filament detachment, resulting in 
slowing of muscle relaxation that clinically characterizes 
NEM6. Given the 8:1 stoichiometry of KBTBD13-actin 
binding, which is close to the 7:1 stoichiometry between 
troponin / tropomyosin and actin, it is possible that 
KBTBD13 acts in concert with those well-known sarco-
meric regulatory proteins to fine-tune muscle contrac-
tion kinetics. Interestingly, deletion of KBTBD13 in mice 
does not lead to slower muscle relaxation, suggesting 
that KBTBD13R408C is a gain-of-function mutation. It 
remains to be shown whether other mutations in this 
gene lead to similar functional deficits and to elucidate 
how defects in muscle relaxation ultimately lead to pro-
duction of nemaline rods (which are recapitulated in the 
mouse KBTBD13R408C knock-in model). 
In 2019, we have also learned that impaired con-
tractility and abnormal cytoskeletal organization pro-
duce secondary nuclear deficits, which structurally – and 
possibly functionally – mimic nuclear abnormalities seen 
in patients with mutations in the nuclear envelope pro-
teins, such as lamins, nesprins, and emerin (Ross et al.,
 
Figure 4. Nuclear abnormalities in a case of myofibrillar myopathy caused by a desmin mutation. Representative electron micrographs 
show marked nuclear abnormalities (a-e) including invaginations of the nuclear membrane (a and b, arrowheads), abnormally dense 
chromatin (the nucleus highlighted by the arrow in b, as well as nuclei in c and d), and nuclear fragmentation (c-e). Granulofilamentous 
material (f), a clue to the correct diagnosis, was seen only focally. Subsequent genetic testing revealed a heterozygous DES gene muta-
tion [c.1237_1239delGAG (p.E413del)]. Scale bars: a and e, 1 µm; b-d, 2 µm; f, 4 µm. 
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2019). Abnormal spacing of myonuclei, nuclear envelope 
defects, and chromatin alterations were present not 
only in the skeletal muscle from patients with two dif-
ferent genetic forms of NM and NM model mice, but 
also in skeletal muscle from patients with acquired (im-
mune-mediated) forms of NM, underscoring that these 
nuclear abnormalities are secondary to impaired con-
tractility rather than a direct consequence of NM muta-
tions. In addition, muscle fibers from both NM patients 
and NM model mice showed extensive cytoskeletal dis-
ruption (disorganized microtubules, mislocalized inter-
mediate filaments composed of desmin, and altered 
cortical microfilaments composed of actin); given that 
treatment with microtubule-disrupting agents was 
shown to alter nuclear shape in vitro, these cytoskeletal 
alterations likely also contribute to nuclear deficits seen 
in the NM muscle. Indeed, we have recently observed 
very similar nuclear defects in a patient with a desmin 
mutation (Fig. 4); thus, secondary nuclear defects (and 
consequent gene expression changes) may be an im-
portant but overlooked cause of muscle dysfunction that 
is more widespread than currently recognized. 
5. Sporadic inclusion body myositis: The role of 
terminally differentiated cytotoxic T cells 
Sporadic inclusion body myositis (sIBM) is the most 
common skeletal myopathy affecting people over the 
age of 50; it typically presents with a weakness of the 
quadriceps and deep finger flexor muscles, has a slowly 
progressive course resulting in eventual loss of mobility, 
and is currently without effective therapy. Pathological-
ly, sIBM shows both inflammatory and myodegenerative 
features (Fig. 5a); together with a lack of response to 
immunosuppressive treatment, this “dual” nature of 
sIBM pathology has led to a long-standing disagreement 
about the role of inflammation in sIBM pathogene-
sis.Three studies published in 2019 (Dzangue-Tchoupou 
et al., 2019; Greenberg et al., 2019; Knauss et al., 2019) 
will likely break this impasse by providing a strong sup-
port for the autoimmune nature of sIBM: starting with 
different questions and using different experimental 
approaches, these studies have demonstrated that ter-
minally differentiated effector memory T cells (so-called 
TEMRA cells) are enriched in sIBM muscle biopsies 
(Greenberg et al., 2019; Knauss et al., 2019) as well as 
peripheral blood of sIBM patients (Dzangue-Tchoupou et 
al., 2019), and that the presence of these cells is fairly 
unique for sIBM when compared to other IIMs [although 
similar cells were also seen in biopsies from two patients 
with severe, treatment-resistant irMyositis (Knauss et 
al., 2019)].  TEMRA cells are positive for CD8, T-bet (a 
transcription factor that drives differentiation of naïve T 
cells into cytotoxic T lymphocytes), CD57 (a marker of 
replicative senescence), and KLRG1 (killer cell lectin-like 
receptor G1; a marker of T cell exhaustion). They contain 
high concentration of cytotoxic enzymes (granzymes and 
perforin) that likely directly cause muscle fiber damage, 
are known to increase in peripheral blood with age, and 
are resistant to corticosteroids and drugs that target 
actively dividing cells (such as methotrexate); the latter 
two characteristics likely provide at least partial explana-
tion for the age dependence and resistance to immuno-
suppression that are characteristic of sIBM. 
In addition to providing insight into sIBM patho-
genesis, these studies have important implications for 
the sIBM diagnosis and treatment. Of particular interest, 
the study by Greenberg at al. (2019) included 10 samples 
from patients diagnosed with polymyositis (PM), an IIM 
that was historically thought to share the sIBM inflam-
matory profile but lack its myodegenerative phenotype 
and its refractoriness to therapy. The existence of PM as 
a distinct IIM subtype has recently been called into ques-
tion, given that most patients diagnosed with PM based 
on the 1975 Bohan & Peter criteria can be reclassified as 
one of the other IIMs [early stage sIBM, immune-
mediated necrotizing myopathy (IMNM), antisynthetase 
syndrome-associated myositis (ASM), or dermatomyo-
sitis (DM)] using the current clinicoseropathologic crite-
ria (Allenbach et al., 2017; Tanboon and Nishino, 2019). 
However, Greenberg and co-authors have demonstrated 
an important difference between their “PM” and sIBM 
samples: while CD8+ lymphocytes invading muscle fibers 
in sIBM biopsies were abundant and CD57-positive, the 
CD8+ T lymphocytes invading muscle fibers in “PM” 
biopsies were sparse and CD57-negative. Additional 
work will be required to establish whether pathologically 
diagnosed PM is a distinct (albeit rare) disease entity or 
whether it corresponds to an early stage of sIBM that 
lacks senescent, CD57+KLRG1+ TEMRA cells and thus 
remains responsive to immunosuppressive therapy. 
Either way, these findings raise a possibility that the 
presence of CD8+CD57+KLRG1+ T cells in an IIM biopsy 
could serve as a prognostic marker of resistance to the 
currently available immunosuppressive therapies, a 
clinically important application that warrants future 
study. In addition, expression of KLRG1 by sIBM TEMRA 
cells may have therapeutic implications: given that this 
protein is not expressed by central memory T cells and 
regulatory T cells, it could be used as a basis for devel-
opment of a future sIBM therapeutic (Greenberg et al., 
2019). 
6. Immune-mediated necrotizing myopathies: 
Mechanisms of cell injury 
Immune-mediated necrotizing myopathies 
(IMNMs) are a unique class of IIMs for which the con
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Figure 5. Distinct patterns of LC3 and p62 immunostaining in sporadic inclusion body myositis (sIBM) and immune-mediated necrotizing 
myopathy (IMNM). A typical sIBM case (a-c) shows inflammatory and myodegenerative changes on H&E staining (a) and dense, largely 
subsarcolemmal protein aggregates and vacuoles on LC3 (b) and p62 (c) immunostaining. In contrast, an IMNM case (d-f) shows ran-
domly distributed degenerating/regenerating fibers and the absence of significant inflammation on H&E (d) and multiple fibers with 
diffuse, finely punctate staining on LC3 (e) and p62 (f) immunostaining. For both cases, H&E stain was performed on cryosections, while 
LC3 and p62 immunohistochemistries were performed on formalin-fixed, paraffin-embedded tissue sections. Scale bars, 50 µm. 
 
sensus clinicoseropathologic criteria were defined at a 
workshop held in 2016 (Allenbach et al., 2018). IMNMs 
have been linked to autoantibodies against signal recog-
nition particle (SRP) and 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR), but approximately one third of 
cases is seronegative and requires histopathologic diag-
nosis (Bergua et al., 2019). Regardless of the serologic 
subtype, pathologic features of IMNM include randomly 
distributed necrotic and regenerating muscle fibers (Fig. 
5d), variable MHC-1 upregulation, sarcolemmal com-
plement deposition, and a scant to absent lymphocytic 
infiltrate. Previous work has shown that in vitro treat-
ment with either anti-SRP or anti-HMGCR antibodies 
leads to impaired myoblast fusion and muscle fiber at-
rophy (Arouche-Delaperche et al., 2017), suggesting that 
these autoantibodies play a causative role in IMNM 
pathogenesis. A study from the same group published in 
2019 has taken the field a step further by demonstrating 
the causative effect of these two antibodies in vivo: mice 
treated with either anti-SRP+ or anti-HMGCR+ patient-
derived plasma develop weakness and necrotizing myo-
pathy that closely resembles human IMNM (Bergua et 
al., 2019). In a further agreement with human disease, 
muscle deficiency is worse following treatment with 
anti-SRP than with anti-HMGCR antibodies, but both 
antisera require functional complement pathway to 
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produce the disease phenotype. Taken together, these 
studies provide a conclusive evidence for the key role of 
type II (antibody- and complement-mediated) immune 
mechanisms in IMNM pathogenesis. 
Interestingly, target antigens of the two known 
IMNM autoantibodies (the signal peptide-binding 54 kDa 
subunit of the SRP ribonucleoprotein complex and 
HGMCR, the rate-limiting enzyme in the cholesterol 
biosynthetic pathway) are both expressed in the ER of all 
cell types (Bergua et al., 2019). Given the ubiquitous 
expression of these antigens, it remains unclear why 
anti-SRP and anti-HMGCR antibodies selectively target 
skeletal muscle in both humans and mice. However, the 
ER localization of both autoantibody targets may be 
significant for IMNM pathogenesis: a 2019 study has 
shown that human IMNM muscle biopsies of any sero-
type show increased ER stress, activation of the unfold-
ed protein response, and upregulation of the chaperone-
assisted selective autophagy (CASA) pathway (Fischer et 
al., 2019). Notably, activation of the CASA pathway in 
IMNMs is associated with a unique pattern of im-
munostaining for autophagy-associated proteins LC3 and 
p62/SQSTM1: instead of the coarse LC3- and p62-
positive vacuoles and protein aggregates seen in au-
tophagic vacuolar myopathies and sIBM [Figs. 5b and 5c; 
also reviewed in (Margeta, 2019)], IMNM biopsies show 
diffusely punctate and often quite strong staining of a 
variable subset of non-necrotic muscle fibers (Figs. 5e 
and 5f). While it remains to be shown how antibody-
mediated cell injury leads to activation of the CASA 
pathway [the impairment of which plays a role in the 
pathogenesis of myofibrillar myopathies; reviewed in 
(Margeta, 2019)], this unique LC3- and p62-staining 
pattern is likely to prove useful in diagnostically chal-
lenging IMNM cases; however, additional work will be 
required to establish its sensitivity and specificity for 
IMNMs relative to other conditions in the histopatholog-
ic differential diagnosis (toxic necrotizing myopathies 
and other IIMs). 
Advances in neuromuscular disease 
diagnostics 
7. Idiopathic inflammatory myopathies: Myo-
sitis-specific antibodies and interferon activation 
signatures 
As already mentioned, IIMs are currently divided 
into four distinct classes - DM, ASM, IMNM, and sIBM - 
based on the most up-to-date clinicoseropathologic 
criteria [first comprehensively outlined in a review by 
Allenbach at al. (2017) and further updated in a recent 
review by Tanboon and Nishino (2019)]. This classifica-
tion has been developed based on advances made over 
the last 5-10 years and is largely (although not entirely) 
based on the association of individual IIM classes with 
different myositis-specific antibodies (MSA); while these 
autoantibodies sometimes directly mediate muscle inju-
ry (as already discussed for IMNMs in discovery #6), 
more often they represent a diagnostically useful epi-
phenomenon / disease marker. The discovery of MSA 
has revolutionized IIM diagnostics because of their high 
specificity, but the sensitivity remains relatively low. For 
example, two retrospective studies of large European 
IIM cohorts published in 2019 found that MSA are nega-
tive in 40-60% of IIM patients (Betteridge et al., 2019; 
Montagnese et al., 2019); in these MSA-negative cases 
(as well as in rare cases with more than one MSA pre-
sent or in cases for which MSA information is lacking), 
muscle biopsy remains the cornerstone of IIM diagnosis. 
Histopathologically, most cases of DM, IMNM, 
ASM, and sIBM are easily distinguishable [for a review of 
up-to-date pathologic criteria, see Tanboon and Nishino 
(2019)]; however, a few entities can create diagnostic 
difficulties. For example, anti-MDA5-associated subtype 
of DM generally lacks perifascicular atrophy (a key diag-
nostic feature of DM; Fig. 6a) and can therefore mimic 
IMNM or even normal muscle (Fig. 6c), while anti-Mi-2-
associated DM shows prominent perimysial inflamma-
tion and perifascicular fiber necrosis that can mimic ASM 
(Fig. 6b). The interferon-induced gene expression signa-
tures associated with different IIM classes, which were 
defined in two separate studies published in 2019 (Pinal-
Fernandez et al., 2019; Rigolet et al., 2019), confirm the 
validity of the current IIM classification and identify 
immunohistochemical markers of these interferon re-
sponses, which will likely prove diagnostically useful. In 
particular, both studies have shown that all subtypes of 
DM (including the histologically atypical cases associated 
with anti-MDA5 and anti-Mi-2 antibodies) show activa-
tion of the type I interferon (INFα/β) pathway and prom-
inent upregulation of IFN1-inducible genes such as MxA 
(myxovirus resistance protein A), which can be used as 
an immunohistochemical marker of the INF1 response. 
In DM, MxA generally shows sarcolemmal staining in 
perifascicular fibers; the exception is anti-MDA5-
associated DM, where MxA staining is scattered or dif-
fuse but not perifascicular (Tanboon and Nishino, 2019). 
In contrast, both ASM cases (regardless of the nature of 
the associated anti-synthetase antibody) and sIBM cases 
show activation of the interferon type II pathway (i.e. 
upregulation of INFγ-inducible genes); MHC-II, an im-
munohistochemical marker of INFγ activation, can be 
used to monitor this pathway in muscle biopsies (Rigolet 
et al., 2019) and could therefore be useful for distin-
guishing ASM from anti-Mi-2-DM in challenging cases. 
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Figure 6. Dermatomyositis (DM) variants. (a) A “classic” DM case shows marked perifascicular fiber atrophy but no significant inflamma-
tion in the perimysium or endomysium; the patient’s antibody status is not known, but the overall clinicopathologic findings fit best 
with the anti-TIF1γ-associated DM. (b) A typical case of anti-Mi-2-associated DM also shows perifascicular atrophy, but could be con-
fused with anti-synthetase syndrome-associated myositis given the presence of perimysial and focally endomysial inflammation, peri-
mysial fragmentation, and patchy necrosis of perifascicular muscle fibers. (c) A case of anti-MDA5-associated DM shows moderate 
processing artifacts but no significant pathologic changes; the only significant abnormality was mild upregulation of MHC-I complex in 
all muscle fibers (not shown). For all three cases, images show representative H&E-stained cryosections. Scale bar, 100 µm. 
 
[Of note, DM muscle biopsies do show a weak activation 
of INFγ pathway (Pinal-Fernandez et al., 2019; Rigolet et 
al., 2019); however, at least for MHC-II proteins that 
activation is several orders of magnitude lower than in 
ASM and sIBM biopsies. Thus, it should be possible to 
optimize MHC-II staining to effectively differentiate 
between DM and ASM cases.] Finally, both studies found 
that IMNM biopsies do not exhibit either type I or type II 
interferon signature, further validating their separation 
into a separate IIM category (Pinal-Fernandez et al., 
2019; Rigolet et al., 2019). Thus, neuromuscular pathol-
ogy laboratories that see a lot of IIM cases should con-
sider adding MxA and MHC-II immunostains to their 
stain repertoire, so that these markers can be evaluated 
in diagnostically challenging IIM cases. 
What are the sources of INFα/β and INFγ that drive 
these differential responses? That remains to be defini-
tively established; however, the most likely candidate 
for the INFα/β source are plasmacytoid dendritic cells, 
which are increased in DM muscle, while the most likely 
candidate for the INFγ source are CD8+ T cells, which 
were observed in a close vicinity of MHC-II-expressing 
fibers in both ASM and sIBM (Rigolet et al., 2019). 
8. Emerging diagnostic techniques 
The reduced cost and widespread availability of 
 advanced genetic testing techniques [such as disease 
gene panels and whole exome sequencing (WES)] have 
led to a dramatic diagnostic improvement for many 
inherited NMDs. However, even with the aid of these 
advanced molecular techniques, 50-75% of presumed 
genetic NMD cases currently remains undiagnosed 
(Cummings et al., 2017); the underlying reasons include 
challenges involved in interpretation of the variants of 
unknown significance and of variants in the genes previ-
ously not linked to human disease, the inability of these 
techniques to detect certain types of genetic alterations 
(such as structural re-arrangements and copy number 
variants), and the lack of coverage of intronic and regu-
latory regions (Gonorazky et al., 2019). In such diagnos-
tically challenging cases, transcriptome analysis (RNA-
seq) will likely prove beneficial. Indeed, a recent study 
has shown that RNA-seq resolved 36% of their panel- 
and/or WES-negative NMD cases (Gonorazky et al., 
2019); an essentially identical diagnostic yield (35%) was 
reported in a 2017 study that used a different NMD 
patient cohort (Cummings et al., 2017). Importantly, 
gene expression is tissue-dependent; thus, the effec-
tiveness of RNA-seq for diagnostic testing hinges on the 
use of disease-relevant source material. In the context of 
genetic muscle disease, biopsied muscle represents the 
ideal specimen, while peripheral blood is inadequate; 
unmodified skin-derived fibroblasts can be useful for 
some diseases (such as congenital muscular dystro-
phies), but the diagnostic yield is substantially enhanced 
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if fibroblasts are transdifferentiated into myotubes in 
vitro (Gonorazky et al., 2019). Importantly, expression of 
the muscle-specific transcripts was significantly lower in 
transdifferentiated myotubes than in the matched mus-
cle biopsy samples for most genes; therefore, muscle 
biopsies will likely remain the gold standard for diagnos-
tic transcriptomics. However, the transdifferentiation 
approach may prove useful when muscle biopsy cannot 
be performed or when accurate diagnosis requires cor-
relation of gene expression patterns between the pro-
band and other family members (Gonorazky et al., 
2019). 
Another approach for improving muscle disease 
diagnostics is based on the use of automated image-
analysis methods and artificial intelligence (AI) tools 
during muscle biopsy evaluations. To this end, a French 
group has recently developed a fully automated macro 
script for Image J that performs muscle fiber measure-
ments (such as total fiber number, type 1 and type 2 
fiber proportion, and muscle fiber diameter) that are 
routinely assessed during muscle biopsy evaluation, but 
are typically estimated and reported in a semi-
quantitative fashion (Reyes-Fernandez et al., 2019). In 
addition to validating the macro script (which analyzes 
images from immunofluorescence-stained sections and 
is available for download as the manuscript supplemen-
tary material), this study has used quantitative mor-
phometry to definitively demonstrate that the size of 
type 2 fibers decreases with age but increases with obe-
sity, an observation that has relevance for routine mus-
cle biopsy interpretation (Reyes-Fernandez et al., 2019). 
Notably, the authors are in the process of adopting their 
macro script for use on immunoperoxidase-stained sec-
tions, which will make it more routinely applicable to 
most pathology practices. 
More provocatively, a study presented at the 2019 
World Muscle Society Congress (Kabeya et al., 2019) has 
shown that a deep neural network model (“AI-based 
muscle histopathologist”) can use images from H&E-
stained slides to differentiate several major muscular 
dystrophies subtypes better than physicians (although 
the study abstract does not indicate whether those phy-
sicians were expert muscle pathologists). While intri-
guing, the validity of these results needs to be replicated 
by future studies. In particular, NMD diagnosis generally 
requires interpretation of many different stains and 
integration of clinical, laboratory, and histopathologic 
findings; thus, it is fairly unlikely that the diagnostic 
proficiency of an “AI-based muscle histopathologist” will 
generalize to a broader set of NMDs. At the same time, 
it is likely that the best diagnostic yield will ultimately be 
achieved through the combined efforts of AI and human 
pathologists, as was previously demonstrated for the 
other fields of medicine that are based on image inter-
pretation (such as radiology). 
Advances in neuromuscular disease 
treatment 
Development of new disease therapies takes dec-
ades of work, with clinical trials that span years and 
report their results thorough multiple papers published 
over time; as such, it is not entirely appropriate to des-
ignate any of the recently approved genetic treatments 
as a 2019 discovery. At the same time, these new treat-
ments were among of the “hottest” NMD advances in 
2019, and therefore had to be included in this review. 
9. A success story: Genetic therapies for spinal 
muscular atrophy 
Spinal muscular atrophy (SMA) is an autosomal re-
cessive neurodegenerative disease that affects the alpha 
motor neurons in the anterior horn of the spinal cord, 
resulting in neurogenic muscle atrophy and weakness; 
the onset of disease varies from the first 6 months of 
age for the most severe infantile form (SMA1) to the 
second or third decade for the mildest form (SMA4). 
SMA is caused by loss-of-function mutations in both 
copies of SMN1 (survival motor neuron 1) gene, but 
clinical phenotype is modified by the presence of the 
paralog gene, SMN2, which yields only a small number 
of full length transcripts (due to a mutation in the exon 7 
that alters gene splicing) and is present in a variable 
number of copies in different individuals. 
The first genetic therapy for SMA, an intrathecally 
delivered antisense oligonucleotide (ASO) called 
nusinersen, was approved in the US in 2016 and in Eu-
rope in 2017 based on the results of clinical trials done 
with SMA1 and SMA2 infants; additional clinical trials for 
other SMA subgroups are still ongoing. [For a succinct 
but comprehensive review of all treatment approaches 
summarized in this section, see (Vita et al., 2019).] 
Nusinersen binds to the SMN2 pre-mRNA downstream 
of exon 7, resulting in an increase in the expression of 
SMN protein and a significant improvement in motor 
function and patient survival. Risdiplam, an orally availa-
ble small molecule therapeutic that also acts as a splicing 
modifier of SMN2 mRNA, is still in clinical trials; howev-
er, based on the promising early results, it has been 
placed on an accelerated pathway for the approval by 
EMA (European Medicines Agency). An alternate ap-
proach for SMA treatment is to directly replace the de-
fective SMN1 gene; this approach has led to develop-
ment of AAV9-SMN (also called AVXS-101 or Zolgensma), 
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an AAV9 (adeno-associated virus 9) vector carrying hu-
man SMN transgene that was approved for SMA treat-
ment by FDA (Federal Drug Administration) in May 2019 
(Al-Zaidy and Mendell, 2019). 
The availability of multiple treatment options rais-
es many interesting questions that will need to be ad-
dressed going forward. Are some of these treatments 
superior to others? (An indirect comparison between 
nusinersen and AVXS-101 has been done and suggests 
that AVXS-101 is more effective (Dabbous et al., 2019); 
however, that study had significant limitations. Thus, a 
direct comparison of these two drugs is needed, but will 
be challenging to perform given the associated cost and 
ethical considerations.) If two treatments are based on 
different genetic strategies, would a combination thera-
py be more effective than either treatment alone? How 
will treatment efficacy differ depending on the SMA 
subtype and the age at which the treatment is started? 
As expected for a neurodegenerative disease, the treat-
ment is more effective if it is initiated before significant 
neuron loss has occurred (De Vivo et al., 2019); depend-
ing on the SMA subtype, this may require perinatal or 
even prenatal diagnosis. Indeed, a large autopsy study 
published in 2019 has shown that SMN protein levels in 
the human spinal cord decline rapidly during develop-
ment, with a critical window that spans from 3 months 
before to 3 months after birth (Ramos et al., 2019); this 
finding highlights the need for development of newborn 
SMA screening programs, which are already being pi-
loted in several different countries (Dangouloff et al., 
2019; Vill et al., 2019). 
10. On the horizon: Genetic therapies for inherit-
ed myopathies 
Aside from SMA, the only currently approved ge-
netic therapies for neuromuscular disease are three new 
drugs for Duchenne muscular dystrophy (DMD), which is 
a severe progressive X-linked muscle disorder caused by 
the lack of membrane-associated dystrophin protein; 
however, based on their rather modest effects to date 
and on the conditional and inconsistent nature of the 
approvals that were rendered by FDA and EMA, these 
treatments have yet to prove their therapeutic utility 
and are best still considered as being “under develop-
ment” (Vita et al., 2019). Ataluren is an orally bioavaila-
ble drug that binds ribosomal RNA and interferes with 
recognition of premature stop codons present in 10-15% 
of DMD patients; it received a conditional approval from 
EMA in 2014, but the evaluation of long-term outcomes 
is still ongoing. The other two conditionally approved 
treatments for DMD are based on the exon-skipping ASO 
technology; the goal of this therapy is to “trick” the 
cellular machinery to restore the reading frame by skip-
ping over the mutant exon, resulting in an internally 
truncated but functional protein. Eteplirsen, which tar-
gets the splice-donor region of exon 51 (mutated in 13% 
of DMD patients), was conditionally approved by FDA in 
2016 but failed to receive an approval from EMA 
(Aartsma-Rus and Goemans, 2019); a phase 3 clinical 
trial to evaluate its efficacy is still ongoing. Golodirsen 
(exon 53; 8% of DMD patients) has been approved by 




cessed on 12/26/2019), while clinical trials for casi-
mirsen (exon 45; 8% of DMD patients) and suvodirsen 
(exon 51) are still ongoing (Vita et al., 2019). Based on 
the animal model studies, similar exon skipping treat-
ments may also prove valuable for limb-girdle and con-
genital muscular dystrophies (Hwang and Yokota, 2019). 
Excitingly, new treatments for other genetic myo-
pathies are also under active development; several dif-
ferent therapeutic strategies are being evaluated 
through ongoing or planned clinical trials and include 
AAV vector-based gene replacement therapies (for X-
linked myotubular myopathy and Pompe disease), ASO-
based therapy aimed at reduction of toxic RNA produc-
tion (for myotonic dystrophy type 1), chaperone therapy 
(for Pompe disease), and the second generation en-
zyme-replacement therapy (also for Pompe disease) 
(Vita et al., 2019). Initial results that are available to date 
are promising; thus, with some luck, at least some of 
these new treatments will prove beneficial enough to be 
covered in a future update. At the same time, all these 
new gene therapies are likely to be highly expensive; for 
example, the list price of nusinersen treatment in the US 
is $750,000 in the first year and $375,000 / year after 
that. Thus, an increase in the availability of genetic ther-
apies raises important socio-economic and ethical ques-
tions that will have to be addressed before their full 
benefits can be realized. 
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